M32.11

Clinical Causes: Autoimmune response in lupus causing inflammation of the heart's inner lining Formation of immune complexes that deposit on heart tissue surfaces Presence of antiphospholipid antibodies increasing clot formation risk Pre-existing damage to heart valves making them more susceptible to inflammation

Key Symptoms: Often asymptomatic or subtle in early stages Heart murmurs detected during physical examinations Symptoms of congestive heart failure such as shortness of breath and fatigue Palpitations or irregular heart rhythms Signs of embolism if clots dislodge, such as sudden limb pain or neurological symptoms

Diagnosis Path: Diagnosis involves a combination of clinical evaluation, imaging, and laboratory tests: - Echocardiography (often with Doppler) to visualize heart valves and detect vegetations or lesions - Blood tests to identify inflammatory markers and lupus activity - Blood cultures, though these are often negative in Libman-Sacks endocarditis since it is sterile - Review of medical history for lupus-related symptoms and previous cardiovascular issues The clinician may also assess for other lupus-related complications to provide comprehensive care.

Treatment Protocols: Managing endocarditis in systemic lupus erythematosus typically includes: - Immunosuppressive medications such as corticosteroids and other agents to control lupus activity - Anticoagulants or antiplatelet drugs to prevent clot formation, especially in patients with antiphospholipid syndrome - Regular monitoring of heart function and valve status - Treating any heart failure symptoms with appropriate cardiac therapies While antibiotics are generally ineffective because Libman-Sacks endocarditis is non-infectious, addressing the underlying lupus activity is key to preventing progression. In some cases, surgical intervention on heart valves may be necessary if significant damage or dysfunction occurs.